These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1568286)

  • 1. Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.
    Cornford EM; Young D; Paxton JW
    Cancer Chemother Pharmacol; 1992; 29(6):439-44. PubMed ID: 1568286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
    Evans SM; Young D; Robertson IG; Paxton JW
    Cancer Chemother Pharmacol; 1992; 31(1):32-6. PubMed ID: 1458557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivative.
    Robertson IG; Palmer BD; Officer M; Siegers DJ; Paxton JW; Shaw GJ
    Biochem Pharmacol; 1991 Oct; 42(10):1879-84. PubMed ID: 1741765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
    Finlay GJ; Wilson WR; Baguley BC
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1695-701. PubMed ID: 2561099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.
    Paxton JW; Young D; Evans SM; Robertson IG; Kestell P
    Cancer Chemother Pharmacol; 1993; 32(4):320-2. PubMed ID: 8324875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
    Finlay GJ; Baguley BC
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):271-7. PubMed ID: 2702982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
    Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
    Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Haldane A; Finlay GJ; Gavin JB; Baguley BC
    Cancer Chemother Pharmacol; 1992; 29(6):475-9. PubMed ID: 1568291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.
    Paxton JW; Young D; Robertson IG
    Cancer Chemother Pharmacol; 1993; 32(4):323-5. PubMed ID: 8324876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photo-enhancement of the mutagenicity of 9-anilinoacridine derivatives related to the antitumour agent amsacrine.
    Iwamoto Y; Ferguson LR; Pearson A; Baguley BC
    Mutat Res; 1992 Jul; 268(1):35-41. PubMed ID: 1378184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat hepatocyte-mediated metabolism of the experimental anti-tumour agent N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide.
    Schlemper B; Siegers DJ; Paxton JW; Robertson IG
    Xenobiotica; 1993 Apr; 23(4):361-71. PubMed ID: 8337894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
    Paxton JW; Jurlina JL
    Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antitumor properties of nitracrine and amsacrine analogs.
    Mazerska Z; Chołody M; Lukowicz J; Wysocka-Skrzela B; Ledóchowski A
    Arzneimittelforschung; 1987 Nov; 37(11):1276-81. PubMed ID: 3326605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials.
    Osman S; Luthra SK; Brady F; Hume SP; Brown G; Harte RJ; Matthews JC; Denny WA; Baguley BC; Jones T; Price PM
    Cancer Res; 1997 Jun; 57(11):2172-80. PubMed ID: 9187117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography.
    Young D; Evans PC; Paxton JW
    J Chromatogr; 1990 Jun; 528(2):385-94. PubMed ID: 2384576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
    Baguley BC; Wakelin LP; Jacintho JD; Kovacic P
    Curr Med Chem; 2003 Dec; 10(24):2643-9. PubMed ID: 14529454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide.
    Robertson IG; Bland TJ
    Biochem Pharmacol; 1993 May; 45(10):2159-62. PubMed ID: 8512597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
    Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
    Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.